RNA Sequencing Services from Zymo Research

Compatible with Any Organism

Transcriptomic Analysis

Applications include but not limited to transcript quantification, differential gene expression and function analysis.

		Number of Genes Detected*
Crops	Common Wheat	48000
	Corn	17200
	Common Grape Vine	14700
Livestock	Cattle	18000
	Red Junglefowl	20500
Vertebrates	Human	17100
	Mouse	14000
	Rat	14200
Microorganisms	*Candida albicans*	5700
	Escherichia coli	3400

*Number of gene with FPKM≥1

Services include everything from RNA extraction all the way to data analysis!

- 5-mC DNA Methylation Analysis
- Epigenetic Aging Clock
- ChIP-Seq
- Microbiomic Analysis

Learn more and inquire about additional services at
www.zymoresearch.com/pages/services

ZYMO RESEARCH

www.zymoresearch.com | info@zymoresearch.com | Toll Free: (888) 882-9682

Overcome challenging samples.

cDNA synthesis you can rely on.

Introducing the new Reliance Select cDNA Synthesis Kit

Don't let difficult samples stand between you and your data. The Reliance Select cDNA Synthesis Kit was designed for samples that contain inhibitors, secondary structure, and degraded RNA, including formalin-fixed paraffin-embedded (FFPE) samples. Our engineered reverse transcriptase generates high-quality cDNA that can be used for sequencing, gene expression, and other downstream applications in as little as 10 minutes. Explore new possibilities with the Reliance Select cDNA Synthesis Kit.

Push the limits of your samples. Learn more at bio-rad.com/RelianceSelect

#ScienceForward

BIO-RAD

MilliporeSigma

Take CRISPR beyond the bench

SygRNA® CRISPR Synthetic Guides

How far your research goes depends on how far your partners can help you take it. That's why we guarantee every SygRNA® guide to perform. And when paired with industry's leading Cas9 protein offering, you have the power to edit with complete confidence.

The perfect sgRNA:

- Predesigned or custom, every guide guaranteed to edit
- HPLC purified for superior editing efficiency
- Unbeatable introductory price

Discover more at
SigmaAldrich.com/CRISPR

32552 7/2020

Sigma-Aldrich®
Lab & Production Materials

GO BEYOND RNA
ARRAYSTAR INC

JUNK or GOLD?

Unlock the Myths of Non-Coding RNAs

In the recent years, the discovery of non-coding RNA (ncRNA) regulatory activities has unleashed alluring opportunities of finding new disease regulators, biomarkers and therapeutic targets. Did you know that Arraystar offers dedicated solutions for ncRNAs, including lncRNAs, circular RNAs, tRNAs, tRFs and more?

LncRNA Microarrays
2019 New Releases: Human V5.0, Mouse V4.0, Rat V3.0

Circular RNA Microarrays
The only practical choice to profile circular RNAs accurately

Epitranscriptomic Microarrays
Quantify the percentage of modifications for mRNAs, LncRNAs and CircRNAs

nrStar™ ncRNA PCR Arrays
For LncRNAs, microRNAs, tRNAs, tRFs, and snoRNAs

We Help You
from Sample
to Data,
featuring annotations and
analyses specialized for
ncRNA biology.

Start Your Non-coding RNA Adventure Now!
www.arraystar.com

AACR
American Association for Cancer Research®

ANNUAL MEETING

APRIL 9-14, 2021

WASHINGTON ★ DC
#AACR21

★ ★ ★ ★ ★ ★ ★



Submit your scientific findings to the world's most comprehensive annual meeting dedicated to the research, prevention, detection, and treatment of cancer.

★ **Abstract Submission Deadline:** Thursday, November 19, 2020

★ **Late-Breaking and Clinical Trials Abstract Submission Deadline:** Monday, January 11, 2021

★ **Become a Member!**
Join the AACR and receive a discount on registration.

VISIT AACR.ORG/AACR2021 FOR MORE INFORMATION AND TO SUBMIT AN ABSTRACT!

We look forward to seeing you!

ABIM CME MOC ACCREDITED

Continuing Medical Education Activity - *AMA PRA Category 1 Credits™* available

AACR.ORG ★ #AACR21

AACR.ORG/AACR2021

DISCOVERY SCIENCE *DRIVING* CLINICAL BREAKTHROUGHS

2001015Aa

AACR CANCER DISPARITIES PROGRESS REPORT 2020

Achieving the Bold Vision of Health Equity for Racial and Ethnic Minorities and Other Underserved Populations



The American Association for Cancer Research is proud to announce the release of the inaugural *AACR Cancer Disparities Progress Report 2020*. This report highlights the current disparities in the burden of cancer within the United States and the research that aims to mitigate these challenges. Some of the recent advances you will learn about include:

Decline in Disparity for Overall Cancer Death Rate between African Americans and Whites



The National Cancer Institute recently revised its eligibility criteria for cancer clinical trials to expand access for previously excluded patients.

Get your FREE copy of the full report by visiting

CancerDisparitiesProgressReport.org

so that you can learn about the many ways in which research is transforming lives.

horizon™
INSPIRED CELL SOLUTIONS



Get to the answer faster with custom oligos by Dharmacon™

Trusted suppliers of long and modified RNA for over 20 years

Flexible design | Rapid turnaround | High yield | Trusted service

Horizon's custom RNA synthesis service offers the flexibility to design long oligos with chemical modifications added at any open position. Our patented ACE-2′ chemistry produces higher yields in less time than any other oligo supplier.

Quality analysis of a custom synthesized 105 nucleotide RNA oligo



(A) UPLC analysis showing >90% pure full-length material. (B) Mass spec analysis illustrating the correct mass.

Contact us to discuss your project.
technical@horizondiscovery.com

A REVOLUTION
in Co-Transcriptional mRNA Capping

CleanCap® demonstrates superior performance versus legacy co-transcriptional capping methods

	Legacy Cap Analogs	CleanCap®
Natural Cap	No ⊖	Yes ⊕
Immunogenic	Yes ⊖	Reduced Immunogenicity ⊕
Capping Efficiency	~70% ⊖	~95% ⊕
Yield/mL Transcription	1.5 mg/mL ⊖	4 mg/mL ⊕
Cost	3 X ⊖	1 X ⊕
Available Therapeutic Licenses	No ⊖	Yes ⊕

CleanCap®

Successful development of mRNA therapeutics relies on reproducible, high-efficiency production of capped mRNA. CleanCap® uses a new co-transcriptional chemical process for the highest level of mRNA capping:



LC-MS Capping Analysis

CleanCap® gives superior activity *in vivo* by mimicking a natural cap



Luciferase mRNA was formulated with Lunar Lipids and injected by tail vein into mice. At 6 hours, luciferase was measured by western blot in mouse liver. Data courtesy of Arcturus Therapeutics.

CleanCap® results in a natural Cap 1 structure that does not stimulate the innate immune system of the host, resulting in unparalleled efficiency *in vivo*. Legacy co-transcriptional capping methods yield a Cap O, an immunogenic cap structure that is poorly expressed *in vivo*.
The results speak for themselves: **CleanCap®, the next generation of cap analogs, provide the most active and least toxic mRNA for your *in vivo* applications.**

Be part of the revolution.

For more information visit: **trilinkbiotech.com/cleancap**

trilinkbiotech.com

TriLink BIOTECHNOLOGIES
part of Maravai LifeSciences